US20100184691A1 - Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange - Google Patents
Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange Download PDFInfo
- Publication number
- US20100184691A1 US20100184691A1 US11/506,521 US50652106A US2010184691A1 US 20100184691 A1 US20100184691 A1 US 20100184691A1 US 50652106 A US50652106 A US 50652106A US 2010184691 A1 US2010184691 A1 US 2010184691A1
- Authority
- US
- United States
- Prior art keywords
- heart failure
- xip
- ncx
- sarcolemmal
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 51
- 230000002401 inhibitory effect Effects 0.000 title claims description 14
- 239000011575 calcium Substances 0.000 title abstract description 71
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract description 7
- 229910052791 calcium Inorganic materials 0.000 title abstract description 7
- 239000011734 sodium Substances 0.000 title description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title description 3
- 229910052708 sodium Inorganic materials 0.000 title description 3
- 230000000747 cardiac effect Effects 0.000 claims abstract description 23
- 102000006889 calcium:sodium antiporter activity proteins Human genes 0.000 claims abstract description 19
- 108040000797 calcium:sodium antiporter activity proteins Proteins 0.000 claims abstract description 19
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 15
- 206010007556 Cardiac failure acute Diseases 0.000 claims abstract description 9
- 230000002708 enhancing effect Effects 0.000 claims abstract description 9
- 206010007625 cardiogenic shock Diseases 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 6
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 32
- 238000011282 treatment Methods 0.000 abstract description 13
- 230000001413 cellular effect Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 32
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 28
- 230000003205 diastolic effect Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 14
- 229960001948 caffeine Drugs 0.000 description 14
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 230000028161 membrane depolarization Effects 0.000 description 13
- 230000001052 transient effect Effects 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000036982 action potential Effects 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 210000002064 heart cell Anatomy 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000001125 extrusion Methods 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000001133 acceleration Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000000107 myocyte Anatomy 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000003185 calcium uptake Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000001424 Ryanodine receptors Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940124975 inotropic drug Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- WGIKEBHIKKWJLG-UHFFFAOYSA-N methanesulfonic acid;2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl carbamimidothioate Chemical compound CS(O)(=O)=O.C1=CC(CCSC(=N)N)=CC=C1OCC1=CC=C([N+]([O-])=O)C=C1 WGIKEBHIKKWJLG-UHFFFAOYSA-N 0.000 description 3
- 230000009090 positive inotropic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- FSEUPUDHEBLWJY-UHFFFAOYSA-N diacetylmonoxime Chemical compound CC(=O)C(C)=NO FSEUPUDHEBLWJY-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241000531891 Alburnus alburnus Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- ZNDMLUUNNNHNKC-UHFFFAOYSA-N G-strophanthidin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)CO)C3C1(O)CCC2C1=CC(=O)OC1 ZNDMLUUNNNHNKC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- ODJLBQGVINUMMR-UHFFFAOYSA-N Strophanthidin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)C=O)C3C1(O)CCC2C1=CC(=O)OC1 ODJLBQGVINUMMR-UHFFFAOYSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 108010090649 exchanger inhibitory peptide Proteins 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003295 lusitropic effect Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 108010059929 phospholamban Proteins 0.000 description 1
- 102000005681 phospholamban Human genes 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000009024 positive feedback mechanism Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000035176 regulation of the force of heart contraction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- ODJLBQGVINUMMR-HZXDTFASSA-N strophanthidin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C=O)CC[C@@]32C)=CC(=O)OC1 ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
Definitions
- the present invention to provides compositions and methods for treating and preventing heart disease by improving cardiac contractile force.
- Heart failure currently affects more than two million Americans and its economic and human toll will continue to increase as the population ages. Congestive heart failure is the most common inpatient diagnosis for patients 65 years old and older, [Funk, 1996 #14], with more than 400,000 new cases reported each year [Cohn, 1991 #15]. The prognosis is poor, with 60% mortality within 5 years [Cohn, 1991 #15], and 23-52% of deaths attributable to fatal arrhythmias (sudden cardiac death; SCD) [Investigators, 1992 #17; Cohn, 1991 #15]. Heart failure is an inability to match cardiac output to physiological demand.
- Heart failure is therefore not a specific disease, but a syndrome that represents the end-point of most cardiac diseases, including ischemic heart disease, cardiomyopathies (dilative, restrictive, or hypertrophic), valvular heart diseases and long term hypertension and diabetes.
- the symptoms of heart failure can also present acutely (i.e. acute heart failure, or cardiogenic shock) in instances as acute myocardial infarction, post cardiac surgery (stunning, hybernation) or post re-vascularization therapy (i.e. reperfusion injury, post thrombolysis, percutaneous transluminal coronary angioplasty or coronary artery by-pass grafting).
- cardiac contractile force depends on the amplitude of the transient rise in calcium during the action potential (i.e. the Ca i transients).
- the chain of events that link membrane depolarization during the action potential to the Ca i transient is called excitation-contraction coupling (ECC).
- ECC excitation-contraction coupling
- SR sarcoplasmic reticulum
- RyR ryanodine receptors
- the subsequent cell shortening and force development will thus depend on both the Ca i transient amplitude and the myolilament sensitivity for Ca.
- the amplitude of the Ca i transients will depend on the amplitude of the trigger I Ca,L as well as the amount of Ca stored in the SR (the SR Ca load, Ca SR ).
- cytosolic Ca 2+ [Ca 2+ ] i ) does not rise sufficiently during the action potential to activate the required myofilament force [Gwathmey, 1987 #109].
- a typical failing heart cell shows a decrease in the ability of the internal stores (the SR) to load with Ca 2+ , due to a downregulation of SERCA [O'Rourke, 1999 #46].
- Another component of altered Ca 2+ handling in both human disease [Studer, 1994 #79] and animal models [Hobai, 2000 #37; Pogwizd, 1999 #42] is an increase in Ca 2+ extrusion from the cell by the NCX due to NCX overexpression.
- NCX overexpression is compensatory or one of the primary deficits.
- One widely held theory has been that NCX overexpression compensated for decreased Ca 2+ re-uptake into the SR in diastole by increasing Ca 2+ extrusion from the cell [Hasenfuss. 1999 #91], which improved relaxation (positive lusitropic), but at the cost of a further depletion of SR Ca 2+ stores (negative inotropic). Further complicating the issue was the observation that NCX overexpression has also been found in hypercontractile models with no SR dysfunction [Sipido, 2000 #36].
- agents used in heart failure exert their beneficial effects by preventing the long term cardiac remodeling (angiotensin convertin enzyme inhibitors, like captopril, and beta adrenergic blockers, like carvedilol) or by interfering with renal and vascular contributory mechanisms (like diuretics and nitrates).
- cardiac remodeling angiotensin convertin enzyme inhibitors, like captopril, and beta adrenergic blockers, like carvedilol
- renal and vascular contributory mechanisms like diuretics and nitrates.
- the long term beneficial effect of beta blockers is evident only after an initial, transient decrease in cardiac inotropy, with negative effects on both physician confidence and patient compliance.
- the need for new, effective positive inotropic drugs is, therefore, hard to overemphasize.
- Gene therapy strategies include altering the ratio of SERCA2a and phospholamban in the heart (pending patent to Rosenzweig, Hajjar, Guerrero, Luis; entitled “Use of agents to treat heart disorders”; Ser. No.: 789,894; filed Feb. 21, 2001).
- NCX has been associated with congestive heart failure since 1989 (e.g. Nakanishi, et al, 1989, Am J Physiol, 257, 2 Pt 2, H349-56.).
- NCX overexpression has been generally thought of as compensatory and beneficial for cell relaxation (e.g. Studer, et al., 1994, Circ Res, 75, 3, 443-53.) and, until now, it has not been envisaged that its inhibition may be beneficial.
- Kanebo, Ltd. of Tokyo, Japan has developed a Na + /Ca 2+ exchange inhibitor compound KB-R7943.
- KB-R7943 is completely non-specific in action and inhibits a variety of ion channels in the cardiac membrane. It has been shown that the compound inhibits predominantly the Ca-entry mode of the Na/Ca exchanger and has no effect on cardiac contractility (Satoh, et al. Circulation 101, 1441-6, 2000). Therefore, it appears that KB-R7943 does not represent a clinically useful drug for the treatment of heart failure, nor has it been proposed to be one.
- the present invention to provides compositions and methods for improving cardiac contractile force by inhibiting the sarcolemmal sodium/calcium exchanger.
- This can be achieved by using either pharmacological sodium/calcium exchange inhibitors, peptides, gene transfer or gene knockdown methodologies such as RNA interference or anti-sense oligonucleotides.
- This method can be used for treatment of both congestive heart failure due to, for example, dilative, hypertrophic or restrictive cardiomyopathy or ischemic heart disease.
- This method can be used for treatment of acute heart failure such as cardiogenic shock. In the context of congestive heart failure, this method can be used for both symptomatic relief and for prevention of progression of heart disease and reduction of mortality.
- compositions and methods of treatment and prevention of heart failure are provided to enhance cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger.
- the method is used for treating congestive heart failure.
- Embodiments of the method of treating congestive heart failure include those where the heart failure is caused by a cardiomyopathy, including embodiments where the cardiomyopathy is dialative, restrictive, or hypertrophic cardiomyopathy.
- the method comprises treating or preventing an acute heart failure.
- a further embodiment of the method is where the acute heart failure is a carcinogenic shock.
- the treatment and prevention includes administering to a subject an effective amount of a pharmaceutical composition useful to inhibit the sarcolemmal sodium/calcium exchanger.
- the pharmaceutical composition comprises at least one peptide.
- the peptide can the formula RRLLFYKYVYKRYRAGKQRG.
- Other embodiments include the method as accomplished by a gene transfer, anti-sense nucleotide techniques, or RNA interference techniques.
- the present invention identifies a new class of positive inotropic drugs, the NCX inhibitors.
- the invention originated from a detailed analysis of the cellular mechanisms responsible for the generation of cardiac contractile force and for its degradation in heart failure, as detailed below.
- One causative mechanism of congestive heart failure is the decreased Ca 2+ re-circulation between cytosol and the internal stores located in the SR. This is due to a reduction of the SR Ca 2+ uptake mechanism, the SR Ca 2+ pump (SERCA) and an increase in sarcolemmal Na + /Ca 2+ exchange.
- SERCA SR Ca 2+ pump
- Ca 2+ extrusion from the cell is enhanced relative to re-uptake into intracellular Ca 2+ stores, resulting in a decrease in the amount of Ca 2+ stored in the SR and available for release.
- One beneficial effect of the enhanced Na + /Ca 2+ exchange is that it helps to prevent excessive prolongation of Ca 2+ removal from the cytoplasm that would be a consequence of the impaired SERCA function. Therefore, a major therapeutic challenge is to decrease Na + /Ca 2+ exchange-mediated Ca 2+ extrusion from the cell without impeding cell relaxation.
- a novel aspect of the invention is that NCX inhibition restores contractility in cardiac cells from failing hearts without a detrimental effect on diastolic Ca 2+ handling.
- the lack of a specific pharmacological inhibitor was circumvented by using a peptide (XIP) that selectively inhibits the Na + /Ca 2+ exchange.
- NCX inhibition was not associated with slowing of relaxation of heart cells. This was due to the restitution of the SR uptake ability in failing cells, secondary to the increase in average Ca i mediated by NCX block.
- Ca i activation of SERCA has been observed previously, but has not been recognized for its importance for heart failure therapy.
- NCX inhibition results in the restoration of the balance of Ca 2+ fluxes toward normal levels, with a greater fraction of Ca 2+ available for release from the cardiac SR.
- the invention specifically pertains to the development of drugs or genetic therapeutic approaches which target Na + /Ca 2+ exchange to improve Ca 2+ handling in muscle.
- the invention encompasses gene transfer methods for expressing exchanger inhibitory peptides (XIP) or XIP mimetic peptides or nucleic acid vectors which inhibit the expression of Na + /Ca 2+ exchanger, as well as pharmacological compounds that have as their predominant effect inhibition of Na + /Ca 2+ exchange.
- FIG. 1 Quantifying NCX block and selectivity.
- FIG. 2 XIP effects on Ca 2 -induced Ca 2+ release.
- FIG. 3 XIP effects on Ca 2+ -induced Ca 2+ release.
- FIG. 4 XIP effect on the Ca 2+ staircase.
- FIG. 5 XIP effects on [Ca 2+ ] i decay
- FIG. 6 The effect of XIP under current clamp conditions
- Congestive heart failure is a disease of increasing incidence and mortality, which has an enormous economic impact worldwide. Nearly five million Americans are currently living with this condition, with 550,000 new cases diagnosed each year. Despite the magnitude of this problem, the treatment options are limited, and the disease has overall a remarkably bleak prognosis, with an average life expectancy of less than 5 years from diagnosis.
- the basis of this disease is constituted by the degradation of performance of the individual heart cells, with changes in multiple cellular mechanisms. Among them, an increase in calcium (Ca) extrusion from the cell by a membrane sodium/calcium (Na + /Ca 2+ ) exchange protein contributes to the defective calcium handling, and leads to the decreased cardiac performance.
- the present invention is a method of treating or preventing heart failure in a subject.
- the method includes enhancing cardiac contractility by inhibiting a sarcolemmal sodium/calcium exchanger.
- the heart failure is a congestive heart failure.
- Congestive heart failures that are treated include those caused by a cardiomyopathy, including restrictive, dilative, and hypertrophic cardiomyopathies.
- the heart failure is an acute heart failure including an acute heart failure that is a cardiogenic shock.
- the method includes administering to the subject an effective amount of a composition useful to inhibit the sarcolemmal sodium/calcium exchanger.
- a composition useful to inhibit the sarcolemmal sodium/calcium exchanger include the composition wherein it comprises at least one peptide, and the embodiment wherein the peptide has the formula RRLLFYKYVYKRYRAGKQRG.
- the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using a gene transfer.
- Further embodiments include the method wherein the gene is coding for a peptide useful to inhibit the sarcolemmal sodium/calcium exchanger.
- the method can have the gene coding for the peptide with the formula RRLLFYKYVYKRYRAGKQRG.
- Another embodiment includes that where the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using RNA interference techniques.
- Yet another embodiment includes that where the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using anti-sense nucleotide techniques.
- One embodiment of the invention is a pharmaceutical composition useful for treating or preventing heart failure.
- the composition includes at least one peptide useful to inhibit the sarcolemmal sodium/calcium exchanger in combination with a pharmaceutically acceptable carrier.
- the peptide can have the formula RRLLFYKYVYKRYRAGKQRG.
- the canine tachycardia-induced model of heart failure was used for the experiments disclosing the invention, which faithfully reproduces the human disease while offering several advantages.
- the course of the disease is reproducible, time points prior to end-stage failure can be examined, and the confounding factors associated with studying human tissues (e.g., variations in the duration, etiology, or treatment) are absent.
- the decreased contractility and fractional shortening, and elevation of end diastolic pressure have been extensively documented in this model [Darniano, 1987 #20; Armstrong, 1986 #19].
- VVI pacemaker Medtronics
- a VVI pacemaker Medtronics
- Pacing at 240 bpm was maintained for 3-4 weeks, during which time the animals developed typical symptoms of heart failure including lethargy, loss of appetite, ascites, etc.
- Hemodynamic decompensation was confirmed by recording left ventricular (LV) pressure waveforms (under anesthesia with 25 mg/Kg tiopental) prior to sacrifice using a micromanometer-tipped LV catheter inserted through the right femoral artery.
- EDP end-diastolic pressure
- the heart was perfused with ice-cold cardioplegic solution, containing (mM): KCl 104; NaCl 32; NaHCO 3 10, taurine 10, BDM (butanedione monoxime) 20, pH 7.4, and quickly excised.
- KCl 104 KCl 104
- NaCl 32 NaHCO 3
- taurine 10 BDM (butanedione monoxime) 20
- pH 7.4 ice-cold cardioplegic solution
- the region of the left ventricular free wall perfused by the left anterior descending coronary artery was excised, cannulated and perfused at 12 ml/min.
- the basic Ca-free isolation solution [Hobai, 1997 #15] contained, in mM:NaCl 130; KCl 4.5; MgCl 2 5; HEPES 23; glucose 21; taurine 20; creatine 5; NaH 2 PO 4 1; Na pyruvate 5; pH 7.25 (titrated with NaOH), at 37° C., oxygenated with 100% O 2 .
- the cardiac muscle was perfused in sequence with: 1) isolation solution with added 8 ⁇ M EGTA for 15 min.; 2) isolation solution with 50 ⁇ M Ca, 1 mg/ml collagenase (type I, 255 U/mg, Worthington Biochemical Corp., Freehold, N.J.) and 0.1 mg/ml protease (type XIV, Sigma Chemical Co., St. Louis, Mo.) for 12 min., and 3) isolation solution containing 100 ⁇ M Ca for 6 min. for washout.
- Chunks of well-digested ventricular tissue from the midmyocardial layer of the ventricle were dissected out (after removing the epicardial and endocardial layers) and cells were mechanically disaggregated, filtered through nylon mesh and stored in modified Tyrode's solution containing 1 mM Ca. The procedure yielded Ca-tolerant quiescent myocytes which survived well for up to 8 hours.
- the external solution contained (mM): NaCl 140; KCl 4; CaCl 2 2; MgCl 2 1, HEPES 5; Glucose 10; niflumic acid 0.1 (to block Ca 2+ -activated Cl ⁇ currents), pH 7.4.
- the pipette solution contained (in mM): K glutamate 125; KCl 19; MgCl 2 0.5; MgATP 5; NaCl 10; HEPES10; pH 7.25 and also 50 ⁇ M indo-I (pentasodium salt, Calbiochem, USA). The liquid junction potential between the pipette and bath was corrected.
- NCX As there is currently no selective, externally applicable inhibitor of NCX (available compounds [Watano, 1996 #69] or inorganic blocking cations [Flobai, 1997 #51] are either non-selective, or preferentially block reverse-mode exchange [Watano, 1996 #69]), cellular responses were compared in the absence and presence of XIP (Li, 1991 #74), added directly to the intracellular solution. XIP has been shown to be an effective NCX blocker under various conditions (i.e., refs [Hobai, 1997 #51; Chin, 1993 #29; Li, 1991 #74]).
- NCX activity was measured as the Ni 2+ -sensitive current elicited by depolarizations from ⁇ 40 mV to various potentials in selective conditions and with [Ca 2+ ], buffered to 200 nmol/L, as shown in FIG. 1 a .
- NCX current was measured selectively with [Ca 2+ ] i buffered to 200 mmol/L[Hobai, 2000 #37] (N, O).
- 10 ( ⁇ ) and 30 ⁇ M ( ⁇ ) XIP inhibited NCX by 45 and 55%, respectively (P ⁇ 0.05 at all potentials except the reversal potential, n 22 cells from 6 animals (22/6), 6/2, 7/2 for control, 10 and 30 ⁇ M XIP), over the entire range of test potentials.
- the external solution was K-free (to block the inward rectifier K + current, and also the Na + /K + pump) and also contained 100 ⁇ M nifiumic acid (to block Ca 2+ -activated Cl ⁇ currents), 10 ⁇ M strophanthidin (Na + /K + pump inhibitor) and 10 ⁇ M nitrendipine (dihydropyridine antagonist).
- the pipette solution contained (mM): CsCl 110, NaCl 20, MgCl 2 0.4, glucose 5, HEPES 5, CaCl 2 1.75 and BAPTA 5.
- the mixture of BAPTA and Ca gave a free [Ca] of 200 nM (calculated using the “Maxchelator” program, D. Bers, Loyola University, Chicago).
- 10 and 30 ⁇ M XIP inhibited NCX by 45 and 55%, respectively (at +40 mV, FIG. 5 a ), and the block was mode-independent.
- NCXIP has been reported to inhibit both the sarcolemmal and SR Ca 2+ pumps in vitro [Enyedi, 1993 #59]. Therefore, it was important to establish that reversal of the failing phenotype was due to a selective effect on NCX.
- NCX was inhibited by a rapid application of a Na + - and Ca 2+ -free external solution, and caffeine was rapidly applied [Bassani, 1992 #66].
- the time constants of [Ca 2+ ] i decay attributable to the sarcolemmal and SR Ca 2+ pumps were assessed during and after washout of caffeine, respectively [Bassani, 1992 #661.
- Cardiac cells isolated from normal (N) or failing (F) hearts were subjected to trains of depolarizations to assess the main mechanisms of Ca 2+ -induced Ca 2+ release (CICR), i.e., trigger Ca 2+ entry through L-type Ca 2+ channels (I Ca,L ), the rate of rise ( ⁇ Ca/ ⁇ t) and amplitude ( ⁇ Ca) of the [Ca 2+ ] i transient, and the SR Ca 2+ load (Ca SR , measured as the integral of NCX current during caffeine application [Hobai, 2000 #371; FIG. 2 ).
- CICR Ca 2+ -induced Ca 2+ release
- the experimental protocol consisted of a train of 0.5 sec depolarizations from ⁇ 80 mV to +10 mV, applied at 0.5 Hz until steady-state, followed by a rapid application of caffeine, to measure SR Ca 2+ load.
- Myocytes from failing hearts cells showed the characteristic Ca 2+ handling deficit, with depressed [Ca 2+ ] i transients and Ca SR , and a normal I Ca,L ( FIGS. 2-3 ).
- Internal equilibration with 10 ⁇ M XIP induced a large increase in the steady-state Ca SR and [Ca 2+ ] i transients, in the absence of any change in I Ca,L .
- FIG. 2 shows the XIP effects on Ca 2 -induced Ca 2+ release.
- FIG. 2 a - d Steady-state membrane currents and [Ca 2+ ] i transients triggered by membrane depolarization (left) or caffeine (right), in myocytes from normal (N) or failing (F) hearts in the absence ( FIG. 2 a - b ) or presence of 10 m XIP ( FIG. 2 c - d ) in the intracellular solution.
- FIG. 3 also shows XIP effects on Ca 2+ -induced Ca 2+ release.
- I Ca,L Average steady-state peak inward I Ca,L ( FIG. 3 a ), Ca SR (as moles Ca 2+ stored in the SR per total cell volume, ( FIG. 3 b ), diastolic and peak systolic [Ca 2+ ] i ( FIG. 3 c ), and ⁇ Ca/ ⁇ t ( FIG. 3 d ) in N( ⁇ ) and F ( ⁇ ), in the absence or presence of 10 or 30 ⁇ XIP.
- I Ca,L was similar in all six groups. At baseline, F cells had decreased [Ca 2+ ] i transients and reduced Ca SR , which were normalized by XIP at 10 or 30 ⁇ M concentrations without affecting diastolic [Ca 2+ ] i .
- FIG. 4 is shown the XIP effect on the Ca 2+ staircase.
- FIG. 4 a shows [Ca 2+ ] i transient amplitude and I Ca,L for the first 10 depolarizations (at 0.5 Hz) after a caffeine application.
- [Ca 2+ ] i transients increased gradually with pacing in N ( ⁇ ) and this effect was slightly accelerated by 10 ( ⁇ ) and 30 ⁇ M ( ⁇ ) XIP.
- FIG. 4 b where the positive Ca 2+ staircase was absent in F ( ⁇ ), but was restored by XIP (either 10, ⁇ or 30 ⁇ M, ⁇ ).
- the positive inotropic effect of XIP occurred without an associated increase in diastolic [Ca 2+ ] i .
- Typical traces exemplifying the decreased ⁇ Ca associated with the increased [Ca 2+ ] i transient at steady-state (light gray trace) vs. first depolarization (black trace) after caffeine in a F cell with 30 ⁇ M XIP.
- FIG. 5 c is shown average data for b.
- Ca i transients were selected equal to 150, 200, 250, and 300% of the first Ca i transient.
- ⁇ Ca of these Ca i transients were fitted and then plotted ⁇ ca against ⁇ Ca.
- NCX is a major Ca 2+ removal mechanism, especially in myocytes from failing hearts, it was anticipated that XIP may decrease the rate of diastolic Ca 2+ decay and adversely affect cell relaxation.
- FIG. 5 c solid circles).
- FIG. 6 shows the effect of XIP under current clamp conditions
- FIG. 6 a is shown typical action potential-driven Ca, transients showing the effect of 30 ⁇ M XIP in F.
- FIG. 6 b steady-state action potential driven Ca i transients (0.25 Hz) were significantly lower in F vs. N.
- FIG. 6 c both the increase in ⁇ Ca and maintenance of diastolic Ca i were reproduced at different stimulation frequencies (square pulses of 100 msec for 0.5-2 Hz and 50 msec for 3 Hz stimulation).
- FIG. 6 a - b shows that action potential—triggered Ca i transients in F cells were significantly smaller than in N, and were normalized by 30 ⁇ M XIP. XIP had a similar, but less pronounced effect in N.
- FIG. 6 c demonstrates that this was indeed the case, and that failing cells in the presence of 30 ⁇ M XIP could be paced up to 3 Hz without development of diastolic Ca overload.
- the present results demonstrate that partial inhibition of NCX is a powerful method for restoring ECC in heart failure. This effect is brought about by an improvement of SR Ca 2+ load and facilitation of the pulse-dependent positive Ca 2+ staircase due to a reduction in the amount of Ca 2+ “stolen” from the cell on each beat by NCX. Secondary Ca 2+ -dependent stimulation of the SR Ca 2+ ATPase rate plays an additional important role in preventing diastolic [Ca 2+ ] i overload.
- This results represent the proof of therapeutic method for the development of NCX inhibitors as a new class of positive inotropic drugs in the treatment of congestive heart failure. Gene transfer technology making myocyte-targeted XIP expression a feasible therapy is also encompassed. While the NCX inhibitor was selective and mode-independent, the positive inotropic effect could be facilitated by a preponderantly forward-mode NCX inhibitor, and/or by block of PMCA (a lesser component of total Ca 2+ efflux).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses a method of enhancing cardiac contractility in a subject with heart failure. The method consists of administering a compound that inhibits the sarcolemmal sodium/calcium exchanger, whose activity is elevated in heart failure. This method results in correction of cellular calcium handling and enhancement of cardiac contractility to healthy levels. This method can be used for treatment of acute heart failure, cardiogenic shock and congestive heart failure.
Description
- This application is a continuation of U.S. provisional application Ser. No. 60/392,601 filed Jun. 28, 2002, and the complete contents of that application are incorporated herein by reference.
- The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license to others on reasonable terms as provided for by the terms of Contract No. R01-HL61711 awarded by the U.S. Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute.
- The present invention to provides compositions and methods for treating and preventing heart disease by improving cardiac contractile force.
- Heart failure currently affects more than two million Americans and its economic and human toll will continue to increase as the population ages. Congestive heart failure is the most common inpatient diagnosis for patients 65 years old and older, [Funk, 1996 #14], with more than 400,000 new cases reported each year [Cohn, 1991 #15]. The prognosis is poor, with 60% mortality within 5 years [Cohn, 1991 #15], and 23-52% of deaths attributable to fatal arrhythmias (sudden cardiac death; SCD) [Investigators, 1992 #17; Cohn, 1991 #15]. Heart failure is an inability to match cardiac output to physiological demand. Heart failure is therefore not a specific disease, but a syndrome that represents the end-point of most cardiac diseases, including ischemic heart disease, cardiomyopathies (dilative, restrictive, or hypertrophic), valvular heart diseases and long term hypertension and diabetes. In addition, the symptoms of heart failure can also present acutely (i.e. acute heart failure, or cardiogenic shock) in instances as acute myocardial infarction, post cardiac surgery (stunning, hybernation) or post re-vascularization therapy (i.e. reperfusion injury, post thrombolysis, percutaneous transluminal coronary angioplasty or coronary artery by-pass grafting).
- A momentous discovery was made in the early 1990s, when it was demonstrated that heart failure is ultimately due to changes at the level of the heart cells, which are unable to develop sufficient contractile force. At a cellular level, cardiac contractile force depends on the amplitude of the transient rise in calcium during the action potential (i.e. the Cai transients). The chain of events that link membrane depolarization during the action potential to the Cai transient is called excitation-contraction coupling (ECC). Central to the current model of ECC in heart lies the process of Ca-induced Ca-release (CICR) [Fabiato, 1983 #26]. During the action potential, membrane depolarization opens sarcolemmal Ca channels and allows Ca entry into the cell (which can be measured as L-type Ca current, LCa,L). Sarcolemmal L-type Ca channels are in close apposition to the intracellular release channels of the sarcoplasmic reticulum (SR, the internal Ca stores), also known as ryanodine receptors (RyR). Entry through L-type Ca channels triggers the opening of the RyR, followed by a large efflux of Ca from the SR into the cytosol. The rise in cytosolic Cai activates the actin-myosin interaction. The subsequent cell shortening and force development will thus depend on both the Cai transient amplitude and the myolilament sensitivity for Ca. In turn, the amplitude of the Cai transients will depend on the amplitude of the trigger ICa,L as well as the amount of Ca stored in the SR (the SR Ca load, CaSR).
- In diastole, heart relaxation is brought about by Ca2+ removal from cytoplasm, mainly by two mechanisms: about 70% of Ca2+ is taken up into the SR though the action of the SR Ca pump, and is made available for next Ca release episode. The
remainder 30% of cytosolic Ca is extruded from the cell by the sarcolemmal sodium/calcium exchanger (NCX). - In failing heart cells, the ECC process is corrupted, and cytosolic Ca2+ ([Ca2+]i) does not rise sufficiently during the action potential to activate the required myofilament force [Gwathmey, 1987 #109]. A typical failing heart cell shows a decrease in the ability of the internal stores (the SR) to load with Ca2+, due to a downregulation of SERCA [O'Rourke, 1999 #46]. Another component of altered Ca2+ handling in both human disease [Studer, 1994 #79] and animal models [Hobai, 2000 #37; Pogwizd, 1999 #42] is an increase in Ca2+ extrusion from the cell by the NCX due to NCX overexpression. However, it has been previously unclear whether NCX overexpression is compensatory or one of the primary deficits. One widely held theory has been that NCX overexpression compensated for decreased Ca2+ re-uptake into the SR in diastole by increasing Ca2+ extrusion from the cell [Hasenfuss. 1999 #91], which improved relaxation (positive lusitropic), but at the cost of a further depletion of SR Ca2+ stores (negative inotropic). Further complicating the issue was the observation that NCX overexpression has also been found in hypercontractile models with no SR dysfunction [Sipido, 2000 #36].
- Despite continuous improvements, the treatment of heart failure is at this time unsatisfactory. Although the foundation of this disease is represented by the decrease in cardiac contractility, only two classes of drugs are approved for use to increase cardiac force (i.e. positive inotropes), cardiac glycosides (like digoxin) and beta-adrenergic agonists (like dobutamine, amrinone or milrinone). Importantly, despite an effective relief of symptoms, the use of these agents has been associated with no change (digoxin) or an increase (beta-adrenergic agonists) in mortality.
- Other classes of agents used in heart failure exert their beneficial effects by preventing the long term cardiac remodeling (angiotensin convertin enzyme inhibitors, like captopril, and beta adrenergic blockers, like carvedilol) or by interfering with renal and vascular contributory mechanisms (like diuretics and nitrates). The long term beneficial effect of beta blockers is evident only after an initial, transient decrease in cardiac inotropy, with negative effects on both physician confidence and patient compliance. The need for new, effective positive inotropic drugs is, therefore, hard to overemphasize.
- Numerous experimental therapeutic strategies have been or are currently evaluated. Gene therapy strategies include altering the ratio of SERCA2a and phospholamban in the heart (pending patent to Rosenzweig, Hajjar, Guerrero, Luis; entitled “Use of agents to treat heart disorders”; Ser. No.: 789,894; filed Feb. 21, 2001).
- The increase in NCX has been associated with congestive heart failure since 1989 (e.g. Nakanishi, et al, 1989, Am J Physiol, 257, 2
Pt 2, H349-56.). NCX overexpression has been generally thought of as compensatory and beneficial for cell relaxation (e.g. Studer, et al., 1994, Circ Res, 75, 3, 443-53.) and, until now, it has not been envisaged that its inhibition may be beneficial. - A recent review (Sipido, et al., “Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy?” Cardiovasc Res 53, 782-805, 2002) discusses the complexity of NCX role in failing hearts, and concludes that “Consequently, can not simply consider block of the exchanger function as a strategy in hypertrophy or heart failure in general”. The authors do not discuss any means for NCX inhibition either.
- Kanebo, Ltd. of Tokyo, Japan has developed a Na+/Ca2+ exchange inhibitor compound KB-R7943. Despite the manufacturer's claims, KB-R7943 is completely non-specific in action and inhibits a variety of ion channels in the cardiac membrane. It has been shown that the compound inhibits predominantly the Ca-entry mode of the Na/Ca exchanger and has no effect on cardiac contractility (Satoh, et al. Circulation 101, 1441-6, 2000). Therefore, it appears that KB-R7943 does not represent a clinically useful drug for the treatment of heart failure, nor has it been proposed to be one.
- The present invention to provides compositions and methods for improving cardiac contractile force by inhibiting the sarcolemmal sodium/calcium exchanger. This can be achieved by using either pharmacological sodium/calcium exchange inhibitors, peptides, gene transfer or gene knockdown methodologies such as RNA interference or anti-sense oligonucleotides. This method can be used for treatment of both congestive heart failure due to, for example, dilative, hypertrophic or restrictive cardiomyopathy or ischemic heart disease. This method can be used for treatment of acute heart failure such as cardiogenic shock. In the context of congestive heart failure, this method can be used for both symptomatic relief and for prevention of progression of heart disease and reduction of mortality.
- Compositions and methods of treatment and prevention of heart failure are provided to enhance cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger. In one embodiment the method is used for treating congestive heart failure. Embodiments of the method of treating congestive heart failure include those where the heart failure is caused by a cardiomyopathy, including embodiments where the cardiomyopathy is dialative, restrictive, or hypertrophic cardiomyopathy.
- In another embodiment the method comprises treating or preventing an acute heart failure. A further embodiment of the method is where the acute heart failure is a carcinogenic shock.
- In one embodiment of the method the treatment and prevention includes administering to a subject an effective amount of a pharmaceutical composition useful to inhibit the sarcolemmal sodium/calcium exchanger. In another embodiment the pharmaceutical composition comprises at least one peptide. The peptide can the formula RRLLFYKYVYKRYRAGKQRG. Other embodiments include the method as accomplished by a gene transfer, anti-sense nucleotide techniques, or RNA interference techniques.
- The present invention identifies a new class of positive inotropic drugs, the NCX inhibitors. The invention originated from a detailed analysis of the cellular mechanisms responsible for the generation of cardiac contractile force and for its degradation in heart failure, as detailed below. One causative mechanism of congestive heart failure is the decreased Ca2+ re-circulation between cytosol and the internal stores located in the SR. This is due to a reduction of the SR Ca2+ uptake mechanism, the SR Ca2+ pump (SERCA) and an increase in sarcolemmal Na+/Ca2+ exchange. In effect, Ca2+ extrusion from the cell is enhanced relative to re-uptake into intracellular Ca2+ stores, resulting in a decrease in the amount of Ca2+ stored in the SR and available for release. One beneficial effect of the enhanced Na+/Ca2+ exchange is that it helps to prevent excessive prolongation of Ca2+ removal from the cytoplasm that would be a consequence of the impaired SERCA function. Therefore, a major therapeutic challenge is to decrease Na+/Ca2+ exchange-mediated Ca2+ extrusion from the cell without impeding cell relaxation.
- A novel aspect of the invention is that NCX inhibition restores contractility in cardiac cells from failing hearts without a detrimental effect on diastolic Ca2+ handling. The lack of a specific pharmacological inhibitor was circumvented by using a peptide (XIP) that selectively inhibits the Na+/Ca2+ exchange. Contrary to predictions, NCX inhibition was not associated with slowing of relaxation of heart cells. This was due to the restitution of the SR uptake ability in failing cells, secondary to the increase in average Cai mediated by NCX block. Cai activation of SERCA has been observed previously, but has not been recognized for its importance for heart failure therapy. By indirectly increasing SR uptake in heart failure, NCX inhibition results in the restoration of the balance of Ca2+ fluxes toward normal levels, with a greater fraction of Ca2+ available for release from the cardiac SR.
- This discovery identifies the Na+/Ca2+ exchange as a new target for heart failure therapy and offers a platform for the development of a new class of agents to improve cardiac muscle contractility. To date, there are no known specific Na+/Ca2+ exchange inhibitor compounds. The invention specifically pertains to the development of drugs or genetic therapeutic approaches which target Na+/Ca2+ exchange to improve Ca2+ handling in muscle. The invention encompasses gene transfer methods for expressing exchanger inhibitory peptides (XIP) or XIP mimetic peptides or nucleic acid vectors which inhibit the expression of Na+/Ca2+ exchanger, as well as pharmacological compounds that have as their predominant effect inhibition of Na+/Ca2+ exchange.
-
FIG. 1 . Quantifying NCX block and selectivity. -
FIG. 2 . XIP effects on Ca2-induced Ca2+ release. -
FIG. 3 . XIP effects on Ca2+-induced Ca2+ release. -
FIG. 4 . XIP effect on the Ca2+ staircase. -
FIG. 5 . XIP effects on [Ca2+]i decay -
FIG. 6 . The effect of XIP under current clamp conditions - Congestive heart failure is a disease of increasing incidence and mortality, which has an enormous economic impact worldwide. Nearly five million Americans are currently living with this condition, with 550,000 new cases diagnosed each year. Despite the magnitude of this problem, the treatment options are limited, and the disease has overall a remarkably bleak prognosis, with an average life expectancy of less than 5 years from diagnosis. The basis of this disease is constituted by the degradation of performance of the individual heart cells, with changes in multiple cellular mechanisms. Among them, an increase in calcium (Ca) extrusion from the cell by a membrane sodium/calcium (Na+/Ca2+) exchange protein contributes to the defective calcium handling, and leads to the decreased cardiac performance. This work describes for the first time how inhibiting the Na4/Ca2− exchange restores the defective Ca2+ signaling and provides a means of doing that as a potential treatment for heart failure. The proof of principle is achieved by partially inhibiting the Na+/Ca2+ exchange using a peptide (exchange inhibitory peptide, XIP), which restores Ca2+ signaling in isolated heart cells from failing hearts. The invention originates the concept of Na/Ca exchange inhibition as a treatment for heart failure.
- The present invention is a method of treating or preventing heart failure in a subject. The method includes enhancing cardiac contractility by inhibiting a sarcolemmal sodium/calcium exchanger.
- In one embodiment the heart failure is a congestive heart failure. Congestive heart failures that are treated include those caused by a cardiomyopathy, including restrictive, dilative, and hypertrophic cardiomyopathies.
- In another embodiment the heart failure is an acute heart failure including an acute heart failure that is a cardiogenic shock.
- In one embodiment, the method includes administering to the subject an effective amount of a composition useful to inhibit the sarcolemmal sodium/calcium exchanger. Further embodiments include the composition wherein it comprises at least one peptide, and the embodiment wherein the peptide has the formula RRLLFYKYVYKRYRAGKQRG.
- Another embodiment is where the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using a gene transfer. Further embodiments include the method wherein the gene is coding for a peptide useful to inhibit the sarcolemmal sodium/calcium exchanger. The method can have the gene coding for the peptide with the formula RRLLFYKYVYKRYRAGKQRG.
- Another embodiment includes that where the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using RNA interference techniques.
- Yet another embodiment includes that where the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using anti-sense nucleotide techniques.
- One embodiment of the invention is a pharmaceutical composition useful for treating or preventing heart failure. The composition includes at least one peptide useful to inhibit the sarcolemmal sodium/calcium exchanger in combination with a pharmaceutically acceptable carrier. The peptide can have the formula RRLLFYKYVYKRYRAGKQRG.
- The canine tachycardia-induced model of heart failure was used for the experiments disclosing the invention, which faithfully reproduces the human disease while offering several advantages. The course of the disease is reproducible, time points prior to end-stage failure can be examined, and the confounding factors associated with studying human tissues (e.g., variations in the duration, etiology, or treatment) are absent. The decreased contractility and fractional shortening, and elevation of end diastolic pressure have been extensively documented in this model [Darniano, 1987 #20; Armstrong, 1986 #19]. Also present are chronic neurohumoral responses typical of heart failure, including the activation of the renin-angiotensin system [Armstrong, 1986 #19], increased norepinephrine levels [Armstrong, 1986 #19], decreased beta-adrenergic receptor density [Kiuchi, 1993 #5], and reduced adenylate cyclase activity [Ishikawa, 1994 #6]. Previous studies have documented the defects in cellular membrane and Ca handling mechanisms [O'Rourke, 1999 #46; Kaab, 1996 #76; Hobai, 2000 #37].
- Induction of heart failure was carried out using protocols approved by the Institution's Animal Care and Use Committee. In brief, a VVI pacemaker (Medtronics) was implanted in mongrel dogs of either sex. Pacing at 240 bpm was maintained for 3-4 weeks, during which time the animals developed typical symptoms of heart failure including lethargy, loss of appetite, ascites, etc. Hemodynamic decompensation was confirmed by recording left ventricular (LV) pressure waveforms (under anesthesia with 25 mg/Kg tiopental) prior to sacrifice using a micromanometer-tipped LV catheter inserted through the right femoral artery. An increased end-diastolic pressure (EDP; N, 4.7±1.0 mmHg vs. F: 29.0±3.9 mmHg; p<0.001, n=10N and 7 F for this and following), slowed rate of pressure rise (dP/dt; N, 2738.1±170.9 mmHg/sec vs. F: 1216.6±89.5 mmHg/sec) and slowed relaxation rate (−dP/dt; N: −3591.7±238.4 mmHg/sec vs. F: −11260.1±85.3 mmHg/sec) were evident in F.
- After left lateral thoracotomy, the heart was perfused with ice-cold cardioplegic solution, containing (mM): KCl 104; NaCl 32;
NaHCO 3 10,taurine 10, BDM (butanedione monoxime) 20, pH 7.4, and quickly excised. The region of the left ventricular free wall perfused by the left anterior descending coronary artery was excised, cannulated and perfused at 12 ml/min. The basic Ca-free isolation solution [Hobai, 1997 #15] contained, in mM:NaCl 130; KCl 4.5;MgCl 25; HEPES 23; glucose 21;taurine 20;creatine 5; NaH2PO 4 1;Na pyruvate 5; pH 7.25 (titrated with NaOH), at 37° C., oxygenated with 100% O2. The cardiac muscle was perfused in sequence with: 1) isolation solution with added 8 μM EGTA for 15 min.; 2) isolation solution with 50 μM Ca, 1 mg/ml collagenase (type I, 255 U/mg, Worthington Biochemical Corp., Freehold, N.J.) and 0.1 mg/ml protease (type XIV, Sigma Chemical Co., St. Louis, Mo.) for 12 min., and 3) isolation solution containing 100 μM Ca for 6 min. for washout. Chunks of well-digested ventricular tissue from the midmyocardial layer of the ventricle were dissected out (after removing the epicardial and endocardial layers) and cells were mechanically disaggregated, filtered through nylon mesh and stored in modified Tyrode's solution containing 1 mM Ca. The procedure yielded Ca-tolerant quiescent myocytes which survived well for up to 8 hours. - Cells were placed in a heated chamber on the stage of an inverted fluorescence microscope (IX70, Olympus, Inc.) and superfused with a physiological salt solution. All experiments were carried out at 37° C. Borosilicate glass pipettes of 1-4 MΩ tip resistance were used for whole-cell recording with an Axopatch 1 D amplifier coupled to a Digidata I 200A personal computer interface (Axon Instruments, Foster City, Calif.) using custom-written software.
- The external solution contained (mM): NaCl 140;
KCl 4;CaCl 2 2;MgCl 2 1,HEPES 5;Glucose 10; niflumic acid 0.1 (to block Ca2+-activated Cl− currents), pH 7.4. The pipette solution contained (in mM): K glutamate 125; KCl 19; MgCl2 0.5;MgATP 5;NaCl 10; HEPES10; pH 7.25 and also 50 μM indo-I (pentasodium salt, Calbiochem, USA). The liquid junction potential between the pipette and bath was corrected. - Cai measurement was performed as described previously [O'Rourke, 1999 #2461 using the K salt form of indo-1. Cellular autofluorescence was recorded before rupturing the cell-attached patch and subtracted prior to determining R (ratio of 405 nm emission/495 nm emission). Cai was calculated according to the equation Cai=Kd β×[(R−Rmin)/(Rmax−R)] [Grynkiewicz, 1985 #73], using a Kd of 844 nmol/L [Bassani, 1995 #87], and experimentally determined Rmin=1, Rmax=4 and β=2.
- XIP (RRLLFYKYVYKRYRAGKQRG) was synthesized by the Biosynthesis and Sequencing Facility, Dept. of Biological Chemistry, Johns Hopkins University, kept as 20 mM stock in ethanol and added to the pipette solution (control experiments had equivalent amount of ethanol added, which had no effect on the parameters measured).
- As there is currently no selective, externally applicable inhibitor of NCX (available compounds [Watano, 1996 #69] or inorganic blocking cations [Flobai, 1997 #51] are either non-selective, or preferentially block reverse-mode exchange [Watano, 1996 #69]), cellular responses were compared in the absence and presence of XIP (Li, 1991 #74), added directly to the intracellular solution. XIP has been shown to be an effective NCX blocker under various conditions (i.e., refs [Hobai, 1997 #51; Chin, 1993 #29; Li, 1991 #74]).
- XIP in concentrations of 10 and 30 μM were used in the experiments, and an estimation of the actual degree of NCX inhibition obtained with these concentrations was needed. In a separate experiment[Hobai, 2000 #37] in normal (N) cells, NCX activity was measured as the Ni2+-sensitive current elicited by depolarizations from −40 mV to various potentials in selective conditions and with [Ca2+], buffered to 200 nmol/L, as shown in
FIG. 1 a. InFIG. 1 a, NCX current was measured selectively with [Ca2+]i buffered to 200 mmol/L[Hobai, 2000 #37] (N, O). 10 (□) and 30 μM (Δ) XIP inhibited NCX by 45 and 55%, respectively (P<0.05 at all potentials except the reversal potential, n=22 cells from 6 animals (22/6), 6/2, 7/2 for control, 10 and 30 μM XIP), over the entire range of test potentials. The external solution was K-free (to block the inward rectifier K+ current, and also the Na+/K+ pump) and also contained 100 μM nifiumic acid (to block Ca2+-activated Cl− currents), 10 μM strophanthidin (Na+/K+ pump inhibitor) and 10 μM nitrendipine (dihydropyridine antagonist). The pipette solution contained (mM): CsCl 110,NaCl 20, MgCl2 0.4,glucose 5,HEPES 5, CaCl2 1.75 andBAPTA 5. The mixture of BAPTA and Ca gave a free [Ca] of 200 nM (calculated using the “Maxchelator” program, D. Bers, Loyola University, Chicago). In these conditions, 10 and 30 μM XIP inhibited NCX by 45 and 55%, respectively (at +40 mV,FIG. 5 a), and the block was mode-independent. - It was also important to estimate the degree of NCX inhibition in the minimally Ca2+ buffered conditions that was used for the main ECC experiments as shown later in
FIGS. 2-6 . With the SR Ca2+ uptake (and thus, indirectly, Ca2+ release) blocked by thapsigargin, membrane depolarizations from −80 to +100 mV elicited reverse-mode NCX-mediated [Ca2+]i increases [Hobai, 2000 #37] (FIG. 1 b, c). Under these conditions, 10 and 30 μM XIP induced 23 and 27% NCX inhibition, respectively (FIG. 1 b, c). AtFIG. 1 b, in N (and in the same experimental conditions as forFIGS. 2-6 ) with I μM thapsigargin, a depolarization from −80 mV to +100 mV induced reverse-mode NCX[Hobai, 2000 #37] (typical traces).FIG. 1 c shows the NCX-induced [Ca2+] rise was inhibited to 77 and 73% of baseline levels by 10 and 30 μM XIP, respectively (n.s., n=8/5, 5/2 and 7/2 for N in control and with 10 and 30 μM XIP, respectively). Thus it was hypothesized that by raising average [Ca2+]i, NCX inhibition directly increases SR Ca2+ uptake to simultaneously correct both SR Ca2+ load and diastolic function. - XIP has been reported to inhibit both the sarcolemmal and SR Ca2+ pumps in vitro [Enyedi, 1993 #59]. Therefore, it was important to establish that reversal of the failing phenotype was due to a selective effect on NCX. In the same experimental conditions as shown later in
FIGS. 2-6 , after a few pulses to load the SR, NCX was inhibited by a rapid application of a Na+- and Ca2+-free external solution, and caffeine was rapidly applied [Bassani, 1992 #66]. The time constants of [Ca2+]i decay attributable to the sarcolemmal and SR Ca2+ pumps were assessed during and after washout of caffeine, respectively [Bassani, 1992 #661. 30 μM XIP did not inhibit either transporter as shown inFIGS. 1 d-1 f). InFIGS. 1 d.-f., a separate experiment was performed to confirm that XIP effect was not due to unspecific effects on other Ca2+ handling mechanisms. With the NCX inhibited by a Nat+-, Ca2+-free external solution, SR release was induced with caffeine. During caffeine application, the only effective Ca2+ extrusion mechanism is the plasmalemmal Ca2+ pump (PMCA), whereas after caffeine removal, SR Ca2+ pump starts also to remove cytosolic Cai effectively [Bassani, 1992 #66]. The time constants of Cai decay corresponding to PMCA and SERCA were not changed in the presence of 30 m XIP. d) Caffeine-evoked Ca2+ transients, e-f) average data. (n=8/4 and 6/2 for N and 9/2 and 7/2 for F, in control and with 30 m XIP, respectively; P=n.s.). The disparity between the XIP sensitivity of the pumps shown earlier and the present findings is likely to be due to differences in the experimental conditions. For example, Enyedi, et al. [Enyedi, 1993 #59] measured PMCA and SERCA in membrane vesicles from rabbit erythrocyte and skeletal muscle preparations, respectively, and after proteolytic activation of PMCA. - Cardiac cells isolated from normal (N) or failing (F) hearts were subjected to trains of depolarizations to assess the main mechanisms of Ca2+-induced Ca2+ release (CICR), i.e., trigger Ca2+ entry through L-type Ca2+ channels (ICa,L), the rate of rise (ΔCa/Δt) and amplitude (ΔCa) of the [Ca2+]i transient, and the SR Ca2+ load (CaSR, measured as the integral of NCX current during caffeine application [Hobai, 2000 #371;
FIG. 2 ). The experimental protocol consisted of a train of 0.5 sec depolarizations from −80 mV to +10 mV, applied at 0.5 Hz until steady-state, followed by a rapid application of caffeine, to measure SR Ca2+ load. Myocytes from failing hearts cells showed the characteristic Ca2+ handling deficit, with depressed [Ca2+]i transients and CaSR, and a normal ICa,L (FIGS. 2-3 ). Internal equilibration with 10 μM XIP induced a large increase in the steady-state CaSR and [Ca2+]i transients, in the absence of any change in ICa,L.FIG. 2 shows the XIP effects on Ca2-induced Ca2+ release. Square voltage clamp pulses (−80 to +10 mV, 0.5 sec, at 0.5 Hz) were applied to isolated cardiac cells. After the Cai transients reached steady-state, the train of depolarizations was stopped and caffeine was applied to measure CaSR (FIG. 2 a-d). Steady-state membrane currents and [Ca2+]i transients triggered by membrane depolarization (left) or caffeine (right), in myocytes from normal (N) or failing (F) hearts in the absence (FIG. 2 a-b) or presence of 10 m XIP (FIG. 2 c-d) in the intracellular solution.FIG. 3 also shows XIP effects on Ca2+-induced Ca2+ release. Average steady-state peak inward ICa,L (FIG. 3 a), CaSR (as moles Ca2+ stored in the SR per total cell volume, (FIG. 3 b), diastolic and peak systolic [Ca2+]i (FIG. 3 c), and ΔCa/Δt (FIG. 3 d) in N(∘) and F (), in the absence or presence of 10 or 30 μXIP. ICa,L was similar in all six groups. At baseline, F cells had decreased [Ca2+]i transients and reduced CaSR, which were normalized by XIP at 10 or 30 μM concentrations without affecting diastolic [Ca2+]i. In control conditions, n25/8 for N and 10/4 for F. For 10 μM XIP, n=14/3 and 10/5; and for 30 μM XIP n=15/4 and 12/2 for N and F, respectively. # P<0.05 between N and F groups for the same experimental condition.* P<0.05 within a group for XIP treatment versus baseline. - A smaller increase was also seen in normal myocytes. At a concentration of 30 an additional Ca increase was observed in both groups; in failing cells ΔCa was increased to 3.86-fold compared with the untreated group (
FIG. 2 c). Importantly, and somewhat unexpectedly, the enhancement of ECC occurred without a significant change in diastolic [Ca2+]i (see later). - At
FIG. 4 is shown the XIP effect on the Ca2+ staircase. After a caffeine release, restarting the train of depolarizations induced gradually increasing cellular Cai transients (i.e. staircase).FIG. 4 a shows [Ca2+]i transient amplitude and ICa,L for the first 10 depolarizations (at 0.5 Hz) after a caffeine application. [Ca2+]i transients increased gradually with pacing in N (∘) and this effect was slightly accelerated by 10 (□) and 30 μM (Δ) XIP. ContrastFIG. 4 b, where the positive Ca2+ staircase was absent in F (), but was restored by XIP (either 10, ▪ or 30 μM, ▴).FIG. 4 c-d shows both diastolic and peak [Ca2+]i are shown for the data presented inFIGS. 4 a and b (n=12/5, 10/3, 9/3 and 11/4, 7/4, 7/2 for N and F, in control and with 10 and 30 μM XIP, respectively). The positive inotropic effect of XIP occurred without an associated increase in diastolic [Ca2+]i. - Immediately after a caffeine release (which unloaded the SR completely [Hobai, 2001 #48], and thus gave a similar starting point in all groups), repetitive square depolarizations induced in N a gradual increase in the [Ca2+]i transients (positive staircase or “treppe”), following SR Ca2+ loading. XIP slightly accelerated the pulse dependent [Ca2+]i increase, as shown in
FIG. 4 for the first 10 pulses, which lead, after 20-30 pulses, to the increased steady-state values shown inFIGS. 2-3 . The positive staircase was characteristically absent in untreated F, but fully restored with the addition of 10 or 30 μM XIP (FIG. 4 b). Again, the increase in the amplitude of the [Ca2+]i transient was associated with a maintained or slightly decreased diastolic [Ca2+]i (FIGS. 4 c-d). - At
FIG. 5 is shown the XIP effects on [Ca2+]i decay One potential adverse effect of NCX inhibition could have been a decrease in diastolic Ca decay and cell relaxation. However, for the steady-state [Ca2+]i transients, XIP induced an unexpected acceleration of diastolic [Ca2+]i removal kinetics (τCa) shown here atFIG. 5 a in parallel with the increase in the amplitude of the [Ca2+]i transient (∘N, F; n values as forFIG. 1 ). AtFIG. 5 b.the relation between τCa and ΔCa was reproduced in individual cells during the development of staircase (as inFIG. 3 ). Typical traces exemplifying the decreased τCa associated with the increased [Ca2+]i transient at steady-state (light gray trace) vs. first depolarization (black trace) after caffeine in a F cell with 30 μM XIP. AtFIG. 5 c. is shown average data for b. During the development of staircase, Cai transients were selected equal to 150, 200, 250, and 300% of the first Cai transient. τCa of these Cai transients were fitted and then plotted τca against ΔCa. In N (∘, n=6/4;) the increase in ΔCa was associated with a significant decrease in τCa (for this and other, identifies the first data group whose τCa was different from that of the first Cai transient). A similar result was seen in F when staircase developed with either 10 or 30 μM XIP (, n=6/4). This relation was reproduced in F cells in which the gradual increase in the [Ca2+]i transients was induced in the absence of XIP, by superfusion with 10 mM Ca2+ Tyrode (♦, n=4/2). This it was hypothesized that, by raising average [Ca2+]i, NCX inhibition directly increases SR Ca2+ uptake to simultaneously correct both SR Ca2+ load and diastolic function. - Since NCX is a major Ca2+ removal mechanism, especially in myocytes from failing hearts, it was anticipated that XIP may decrease the rate of diastolic Ca2+ decay and adversely affect cell relaxation. However, the results indicated the contrary: at steady-state, the time constant of decay of the [Ca2+]i transient upon repolarization to the holding potential (τca; i.e., the combined NCX and SERCA actions) was decreased by XIP in both groups (
FIG. 5 a). This indicated that NCX inhibition was associated with an unexpected increase in the rate of SR Ca2+ uptake (which was also consistent with the large increase in CaSR). - Upon closer inspection, τCS acceleration proved to be dependent not directly on XIP, but secondary to the increase in [Ca2+]i (
FIG. 5 b). In normal cells, during the development of the Ca2+ staircase (as inFIG. 4 ), the increase in peak [Ca2+]i was reproducibly associated with an acceleration of τca (FIG. 5 c, open circles), as was previously described (i.e. ref [Schouten. 1990 #77]) and attributed to SERCA activation (i.e. sensitive to thapsigargin [Bassani. 1995 #64]). The same relation was found in failing cells, when the staircase was recovered in the presence of XIP (e.g.FIG. 5 b for typical traces;FIG. 5 c, solid circles). Finally, and clearly demonstrating that the acceleration of Cai decay was not due to XIP in itself, but secondary to the ΔCa increase,FIG. 5 c shows it could be reproduced in F cells in which the increase in the [Ca2+]i transients was induced by an increase in external Ca2+ concentration, in the absence of XIP (FIG. 5 c, solid diamonds). - Ca2+-mediated SERCA activation was first described by Schouten in 1990 [Schouten, 1990 #77], and later coined “activity dependent acceleration of relaxation” [Bassani, 1995 #64]. Subsequent studies suggested it is probably an indirect mechanism, although the nature of the [Ca2+]i-sensitive mediator is still unclear. One possible mechanism suggested by some [Bassani, 1995 #64], but not all [Kassiri, 2000 #981 studies was calmodulin-dependent phosphorylation. Regardless of the mechanistic details, [Ca2+]i-mediated SERCA activation represents an effective autoregulatory mechanism that protects against cytosolic [Ca2+]i overload. It is also a positive feedback mechanism, in which increased SR Ca2+ release and uptake potentiate each other, a likely explanation for the large inotropic effect induced by a relatively modest (23-27%) degree of NCX block in both N and F.
-
FIG. 6 shows the effect of XIP under current clamp conditions AtFIG. 6 a is shown typical action potential-driven Ca, transients showing the effect of 30 μM XIP in F. AtFIG. 6 b, steady-state action potential driven Cai transients (0.25 Hz) were significantly lower in F vs. N. 30 μM XIP significantly increased the Cai transients in F and had a similar trend in N (n=9/3 and 5/2 for N and 8/4 and 4/2 for F, in control and with 30 μM XIP, respectively). AtFIG. 6 c, both the increase in ΔCa and maintenance of diastolic Cai were reproduced at different stimulation frequencies (square pulses of 100 msec for 0.5-2 Hz and 50 msec for 3 Hz stimulation). - While the present experiments were designed to assess selectively CICR at the maximum ICa,L amplitude, an action potential driven Cai transient would likely include a component due to Ca2+ entry through the NCX, which is likely to be relatively larger in F than in N [Dipla, 1999 #47]. Therefore it was of interest to determine if the positive inotropic effect of XIP was also evident in F cells during trains of action potentials in current clamp conditions.
FIG. 6 a-b shows that action potential—triggered Cai transients in F cells were significantly smaller than in N, and were normalized by 30 μM XIP. XIP had a similar, but less pronounced effect in N. - In addition, it was important to know whether the effects of XIP, and especially the maintenance of diastolic Cai levels were still present when the cell was paced at higher frequencies, when the shortened diastole requires an increased rate of Ca extrusion.
FIG. 6 c demonstrates that this was indeed the case, and that failing cells in the presence of 30 μM XIP could be paced up to 3 Hz without development of diastolic Ca overload. - In summary, the present results demonstrate that partial inhibition of NCX is a powerful method for restoring ECC in heart failure. This effect is brought about by an improvement of SR Ca2+ load and facilitation of the pulse-dependent positive Ca2+ staircase due to a reduction in the amount of Ca2+ “stolen” from the cell on each beat by NCX. Secondary Ca2+-dependent stimulation of the SR Ca2+ ATPase rate plays an additional important role in preventing diastolic [Ca2+]i overload. This results represent the proof of therapeutic method for the development of NCX inhibitors as a new class of positive inotropic drugs in the treatment of congestive heart failure. Gene transfer technology making myocyte-targeted XIP expression a feasible therapy is also encompassed. While the NCX inhibitor was selective and mode-independent, the positive inotropic effect could be facilitated by a preponderantly forward-mode NCX inhibitor, and/or by block of PMCA (a lesser component of total Ca2+ efflux).
Claims (18)
1. A method of treating or preventing heart failure in a subject, comprising:
enhancing cardiac contractility by inhibiting a sarcolemmal sodium/calcium exchanger.
2. The method of claim 1 wherein the heart failure is a congestive heart failure.
3. The method of claim 1 wherein the heart failure is an acute heart failure
4. The method of claim 3 wherein the acute heart failure is a cardiogenic shock.
5. The method of claim 2 wherein the congestive heart failure is caused by a cardiomyopathy.
6. The method of claim 5 wherein the cardiomyopathy is a dilative cardiomyopathy.
7. The method of claim 5 wherein the cardiomyopathy is a restrictive cardiomyopathy.
8. The method of claim 5 wherein the cardiomyopathy is a hypertrophic cardiomyopathy.
9. The method of claim 1 , wherein the method comprises administering to the subject an effective amount of a composition useful to inhibit the sarcolemmal sodium/calcium exchanger.
10. The method of claim 9 , wherein the composition comprises at least one peptide.
11. The method of claim 10 , wherein the peptide has the formula RRLLFYKYVYKRYRAGKQRG (SEQ ID NO: 1).
12. The method of claim 1 , wherein the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using a gene transfer.
13. The method of claim 12 wherein the gene is coding for a peptide useful to inhibit the sarcolemmal sodium/calcium exchanger.
14. The method of claim 13 , when the gene is coding for the peptide with the formula RRLLFYKYVYKRYRAGKQRG (SEQ ID NO: 1).
15. The method of claim 1 , wherein the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using RNA interference techniques.
16. The method of claim 1 , wherein the method comprises enhancing cardiac contractility by inhibiting the sarcolemmal sodium/calcium exchanger using anti-sense nucleotide techniques.
17. A pharmaceutical composition useful for treating or preventing heart failure comprising at least one peptide useful to inhibit the sarcolemmal sodium/calcium exchanger in combination with a pharmaceutically acceptable carrier.
18. The composition according to claim 17 wherein the peptide has the formula RRLLFYKYVYKRYRAGKQRG (SEQ ID NO: 1).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/506,521 US20100184691A1 (en) | 2002-06-28 | 2006-08-18 | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39260102P | 2002-06-28 | 2002-06-28 | |
US10/610,735 US7109169B2 (en) | 2002-06-28 | 2003-06-30 | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
US11/506,521 US20100184691A1 (en) | 2002-06-28 | 2006-08-18 | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/610,735 Continuation US7109169B2 (en) | 2002-06-28 | 2003-06-30 | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100184691A1 true US20100184691A1 (en) | 2010-07-22 |
Family
ID=30118364
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/610,735 Expired - Fee Related US7109169B2 (en) | 2002-06-28 | 2003-06-30 | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
US11/506,521 Abandoned US20100184691A1 (en) | 2002-06-28 | 2006-08-18 | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/610,735 Expired - Fee Related US7109169B2 (en) | 2002-06-28 | 2003-06-30 | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
Country Status (1)
Country | Link |
---|---|
US (2) | US7109169B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105123670B (en) | 2007-02-17 | 2018-12-14 | 哈佛学院董事会 | For carrying out the composition and method of tissue preserration |
CN102088977A (en) * | 2008-02-15 | 2011-06-08 | 哈佛学院董事会 | Cardioplegia solution for cardiac surgery |
CA2715634A1 (en) * | 2008-02-15 | 2009-08-27 | President And Fellows Of Harvard College | Blood substitute solution |
CN117815360A (en) * | 2024-01-08 | 2024-04-05 | 哈尔滨医科大学附属第一医院 | Application of Spexin active polypeptide in preparation of medicines for enhancing myocardial contractility |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025193A (en) * | 1996-03-15 | 2000-02-15 | Allegheny University Of The Health Sciences | Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression |
EP1208847B8 (en) * | 1996-07-30 | 2007-02-14 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions |
IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
-
2003
- 2003-06-30 US US10/610,735 patent/US7109169B2/en not_active Expired - Fee Related
-
2006
- 2006-08-18 US US11/506,521 patent/US20100184691A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040009894A1 (en) | 2004-01-15 |
US7109169B2 (en) | 2006-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tanaka et al. | The potential for renoprotection with incretin-based drugs | |
Choate et al. | Peripheral vagal control of heart rate is impaired in neuronal NOS knockout mice | |
Kirchengast et al. | Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling | |
JP2008543947A (en) | Thiol-sensitive positive inotropic material | |
EP3463574B1 (en) | Compositions and methods for treating pulmonary vascular disease | |
Yeves et al. | Physiological cardiac hypertrophy: Critical role of AKT in the prevention of NHE-1 hyperactivity | |
Ren et al. | Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca2+ and NO | |
HU229871B1 (en) | Loratidine derivative for use of treating allergic rhinitis | |
Shah et al. | Angiotensin-(1–7) stimulates high atrial pacing-induced ANP secretion via Mas/PI3-kinase/Akt axis and Na+/H+ exchanger | |
Dschietzig et al. | The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of Gi-phosphoinositide-3 kinase signaling | |
US20100184691A1 (en) | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange | |
Rajani et al. | Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion | |
Funk et al. | Diabetes disturbs functional adaptation of the remote myocardium after ischemia/reperfusion | |
Capasso et al. | Alterations in ANG II responsiveness in left and right myocardium after infarction-induced heart failure in rats | |
El‐Omar et al. | Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy | |
US20030229007A1 (en) | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia | |
JP2022544718A (en) | Compositions and methods for treating septic cardiomyopathy | |
JP2003095977A (en) | Therapeutic agent or prophylactic against disease associated with functional disorder of muscular contraction and relaxation | |
Boyden et al. | Would modulation of intracellular Ca2+ be antiarrhythmic? | |
WO2014172372A1 (en) | Treatment for dopaminergic disorders | |
Bers et al. | Na/Ca exchange and the sarcolemmal Ca-pump | |
Kumar | Cardiac Myosin Binding Protein-C phosphorylation Regulates Calcium Homeostasis | |
JPH09255589A (en) | Stress suppressant | |
Norby et al. | Insulin-Like Growth Factor I Attenuates Diabetes-Induced Cardiac Contractile Dysfunction in Ventricular Myocytes | |
Yuan | The Role of Junctin in the Regulation of Cardiac Function and Sarcoplasmic Reticulum Calcium Cycling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |